skip to Main Content

Study team appointed for the new UK EQ-5D-5L valuation study

The research team for the new EQ-5D-5L valuation study for the United Kingdom has been finalised. This team will bring significant experience and expertise to the valuation study. They were carefully selected by the project’s Steering Group and come from across the United Kingdom, thereby helping to ensure regional coverage for the study. Donna Rowen from the University of Sheffield was appointed as Principal Investigator.

The lead investigators at each collaborating site are:

  • Nathan Bray (Centre for Health Economics and Medicines Evaluation, Bangor University)
  • David Meads (Academic Unit of Health Economics, Leeds Institute for Health Sciences, University of Leeds)
  • Ciaran O’Neill (Centre for Public Health, Queens University Belfast, Belfast)
  • Donna Rowen (School of Health and Related Research, University of Sheffield)
  • Koonal Shah (PHMR, London)
  • Yaling Yang (Nuffield Department of Primary Care Health Sciences, University of Oxford)

The Principal Investigator, Donna Rowen, welcomed the appointments, “The UK research team working across 6 sites are looking forward to collaborating together to generate the much needed EQ-5D-5L value set for the UK.”

The newly appointed research team will start working on the study protocol, supported by the international valuation study protocol (EQ-VT) support team from the EuroQol Research Foundation. Independent Quality Control will be built in at every stage, with reviews taking place at every study milestone. Data collection is expected to begin in early 2021.

COVID-19 is likely to have an impact on the conduct of the study. Researchers of the EuroQol Group are investigating methods for collecting EQ-VT data safely, in close consultation with the Steering Group and the study team.

For a listing of the full study team and more details about the study and its governance please go to the UK EQ-5D-5L valuation study Blog on the EuroQol website, which will be updated regularly.

NICEs current position on EQ-5D-5L: Prior to the completion and publication of the new valuation study, the interim position in England regarding the use of the EQ-5D-5L for companies, academic groups, and others preparing evidence submissions for NICE can be viewed on their website.

Steering Group: The Steering Group comprises representatives from the EuroQol Research Foundation, National Institute for Health and Care Excellence (NICE), Department of Health and Social Care, NHS England and academic experts. The list of members can be found on the Blog.

About valuation studies: The new valuation study will provide a UK value set for the EQ-5D-5L. The value set will provide values (weights) for EQ-5D-5L health state descriptions according to the preferences of the UK general population. These are used in the calculation of quality adjusted life years (QALYs) that inform economic evaluations of healthcare interventions.

About EuroQol: The EuroQol Group is committed to supporting scientific endeavours that further the measurement and valuation of health and advance the use of measures like the EQ-5D-5L to benefit patients and inform decision makers. For further information please do not hesitate to contact us.

Back To Top